PTGS2 and osteosarcoma: Additionally, nine studies with 424 osteosarcoma patients discovered a significant correlation was observed between COX‐2 expression and clinical stage (stage 3–4 vs. stage 1–2: OR = 4.89, 95% CI = 2.57–9.30, P < 0.001) (Fig. 3).